Abstract

Pharmacogenomics has emerged as a powerful tool in the treatment of depression, offering personalized approaches to medication selection and dosing based on individual genetic profiles. This abstract explores the role of pharmacogenomics in depression treatment, highlighting its potential to enhance efficacy, minimize adverse reactions, and expedite the path to effective symptom management. By understanding how genetic variations influence drug metabolism and response, clinicians can tailor treatment strategies to each patient, ultimately improving outcomes and revolutionizing mental health care. Despite challenges such as cost and accessibility, pharmacogenomics represents a promising avenue for precision medicine in depression treatment, paving the way for more targeted and personalized interventions in the quest for better mental health outcomes.